

Second Site Added to Adult Clinical Study

Perth, Western Australia, 26 February 2016 -- ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received approval to enrol adult patients at the Wesley Hospital in Brisbane, Australia. The Wesley Emergency Centre (WEC) is one of the largest private emergency departments in Australia.

The WEC will be the second site participating in ResApp's adult clinical study. The study will gather data from adults presenting to the emergency department with respiratory conditions such as upper respiratory tract infections, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease. The aim of the study is to demonstrate that ResApp's technology, shown to be highly accurate for diagnosis of childhood respiratory conditions, can be extended to adults.

Enrolment at the first site, Joondalup Health Campus (JHC), is progressing very well, with 106 subjects (60 confirmed respiratory disease cases and 46 control cases) enrolled since the study was started in December 2015. The study is targeting total enrolment of 400 patients. The clinical data from both the WEC and JHC will be analysed by the team led by Associate Professor Udantha Abeyratne at The University of Queensland with preliminary results expected in the first half of calendar 2016.

- ENDS -

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

About ResApp Health Limited

ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates



Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to extend the study to adults. Markets for ResApp's technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.

For more information on ResApp, visit www.resapphealth.com.au